Peptides for thyroid, anemia, and perimenopause: what's real?

What's this video probably claiming?

Based on the hashtag combination, @fullonkaren is likely positioning peptide therapy, possibly CJC-1295, ipamorelin, or GHK-Cu, as supportive tools for women dealing with thyroid dysfunction, anemia, and the hormonal turbulence of perimenopause or menopause. The framing around #eatlessmovemore and #weightlossjouney suggests she may be threading peptides into a broader metabolic narrative, implying they help with fatigue, body composition, or hormonal balance when conventional approaches fall short. This is a recognizable content pattern: a relatable woman in midlife, struggling with overlapping symptoms that doctors allegedly dismiss, finding relief through peptide stacks. The audience this reaches is real, the frustration is real, and the symptom overlap between thyroid dysfunction, iron-deficiency anemia, and perimenopause is genuinely complex. Whether the peptide claims hold up is a different question entirely.

What does the science actually show?

Let's be specific about what evidence exists, because the peptide category is not monolithic. GHK-Cu has genuine wound healing and anti-inflammatory data, largely in vitro or in small animal studies (Pickart and Margolina, 2018, Biomolecules). BPC-157 shows consistent gut and tissue repair signals in rodent models but has zero published human RCTs as of 2024. CJC-1295 combined with ipamorelin does stimulate growth hormone pulses in humans, with a 2006 study by Ionescu and Frohman (Journal of Clinical Endocrinology and Metabolism) showing GH area-under-the-curve increases, but this was in healthy adults, not perimenopausal women with thyroid comorbidities. For thyroid function specifically, no peer-reviewed human trial has tested any of these peptides as a primary or adjunct intervention. Iron-deficiency anemia has established treatment pathways. Claiming peptides address it is unsupported.

Where does the social media noise diverge from clinical reality?

The noise diverges in three specific ways. First, symptom conflation: fatigue, weight gain, brain fog, and mood shifts appear in hypothyroidism, iron deficiency, and perimenopause, and peptide advocates often treat this overlap as proof that one intervention handles all of it. That is not how any of this works. Second, the growth hormone angle gets oversold. Yes, GH secretagogues like ipamorelin increase GH pulses. But GH itself does not reliably reverse perimenopausal body composition changes when studied in isolation. A 2019 Cochrane review on GH for adults found modest lean mass gains with significant side effect profiles including edema and insulin resistance. Third, anemia does not have a peptide solution. Serum ferritin below 30 ng/mL needs iron repletion, dietary changes, or investigation of bleeding sources, not a peptide stack. Content that bundles anemia into a peptide protocol should raise immediate red flags.

What should you actually know?

If you are a woman in perimenopause with suspected thyroid issues or anemia, the starting point is bloodwork, not a peptide protocol. TSH, free T3, free T4, a complete iron panel including ferritin, and an estradiol and FSH draw give you actual data to act on. Peptides are not regulated by the FDA for these indications, and compounded versions vary in purity and concentration between pharmacies. The International Peptide Society and most endocrinologists would agree the evidence base does not currently support using peptides as primary therapy for thyroid dysfunction or anemia. That does not mean peptides have no role in a supervised protocol, but that role should be clearly defined, not extrapolated from hashtag clusters and personal anecdotes. A telehealth provider who orders appropriate labs and explains risk-benefit tradeoffs is a different category from a TikTok video linking fatigue to a peptide shopping list.